US 7,320,787 B2
Redirection of cellular immunity by protein tyrosine kinase chimeras
Brian Seed, Boston, Mass. (US); Charles Romeo, Belmont, Mass. (US); and Waldemar Kolanus, Watertown, Mass. (US)
Assigned to The General Hospital Corporation, Boston, Mass. (US)
Filed on May 20, 2002, as Appl. No. 10/151,193.
Application 10/151193 is a division of application No. 08/889712, filed on Jul. 07, 1997, granted, now 6,392,013.
Application 08/889712 is a division of application No. 08/394912, filed on Feb. 24, 1995, granted, now 6,004,811.
Application 08/394912 is a continuation of application No. 08/093210, filed on Jul. 16, 1993, abandoned.
Prior Publication US 2003/0053994 A1, Mar. 20, 2003
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 48/00 (2006.01); C12N 15/63 (2006.01); C12N 5/08 (2006.01)
U.S. Cl. 424—93.21  [424/93.2; 424/93.1; 435/325; 435/366; 435/372.3; 435/455; 435/320.1] 4 Claims
 
1. A method of destroying an HIV-infected cell in a human, said method comprising administering to said human an effective amount of autologous cytotoxic T lymphocytes, each of said autologous cytotoxic T lymphocytes expressing a membrane-bound, proteinaceous chimeric receptor, comprising (a) an intracellular portion of a Syk protein-tyrosine kinase which is capable of signalling said autologous cytotoxic T lymphocyte to destroy a receptor-bound HIV-infected cell and (b) an extracellular portion comprising a portion of CD4 which is capable of specifically recognizing and binding said HIV-infected cell, whereby each of said autologous cytotoxic T lymphocytes is capable of specifically recognizing and destroying said HIV-infected cell.